Healthcare R&D
Our research scientists are hard at work on groundbreaking medicines and technologies to treat everything from cancer, multiple sclerosis and infertility to colds and pains. Wherever there is a medical need, our highly experienced research and development team hopes to meet it. Learn more
Biopharmaceuticals
Biopharmaceuticals
Allergopharma – Allergen Immunotherapy
Allergopharma – Allergen Immunotherapy
Life Science R&D
R&D focus: Reimagining new ways to meet the needs of our customers
Innovation is at the core of the value that we deliver to our customers. Our Life Science business is research driven and innovation focused. In 2016, we invested 260 million Euro in R&D which supported our innovation in launching 2,100 products – products designed to meet our customers' most unmet needs – from antibodies to water purification systems.
The ability to innovate is the core of our culture across all three of our businesses; Research Solutions, Process Solutions and Applied Solutions. Learn more
Performance Materials R&D
R&D focus: Keeping the world’s performance materials on the cutting edge
Our performance materials business is an innovation leader, constantly producing new technologies and new markets for our customers, often through partnerships across industries. We have come up with groundbreaking liquid crystal displays and windows, effect pigments for coatings and color cosmetics and high-tech materials for use in integrated circuits. Learn more
Related News
View All News-
Press Releases
Merck KGaA, Darmstadt, Germany Announces Opening of its Life Science Business ...
Merck KGaA, Darmstadt, Germany today announced the opening of a M Lab™ Collaboration Center in Shanghai, the largest of nine centers worldwide operated by the company’s Life Science business.
2020/07/10
-
Press Releases
Merck KGaA, Darmstadt, Germany to Develop Automated Diagnostic Tool for Neglected ...
Combined efforts aim to develop an artificial intelligence (AI) technology that detects both schistosomiasis and soil-transmitted helminthiasis
2020/07/02
-
Press Releases
FDA Approves BAVENCIO as First-Line Maintenance Treatment for Patients with ...
Merck KGaA, Darmstadt, Germany and Pfizer Inc. today announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BAVENCIO® (avelumab).
2020/06/30